Literature DB >> 23007024

Notching up a new therapeutic strategy for non-small cell lung carcinoma (NSCLC).

Antonio Maraver, Manuel Serrano.   

Abstract

Our results open a new therapeutic opportunity to treat NSCLC using GSIs. Interestingly, GSIs have been used in long-term treatments in Alzheimer´s patients without major side effects (although without improving the course of the disease). The accumulated knowledge on the pharmacology of GSIs should pave the way to test these compounds in NSCLC patients.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23007024      PMCID： PMC3660059          DOI： 10.18632/oncotarget.671

Source DB:  PubMed          Journal:  Oncotarget        ISSN： 1949-2553


  10 in total

1.  Chromosome 19 translocation, overexpression of Notch3, and human lung cancer.

Authors:  T P Dang; A F Gazdar; A K Virmani; T Sepetavec; K R Hande; J D Minna; J R Roberts; D P Carbone
Journal:  J Natl Cancer Inst       Date:  2000-08-16       Impact factor: 13.506

2.  c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma.

Authors:  Rafael B Blasco; Sarah Francoz; David Santamaría; Marta Cañamero; Pierre Dubus; Jean Charron; Manuela Baccarini; Mariano Barbacid
Journal:  Cancer Cell       Date:  2011-04-21       Impact factor: 31.743

Review 3.  gamma-Secretase in biology and medicine.

Authors:  Michael S Wolfe
Journal:  Semin Cell Dev Biol       Date:  2008-12-31       Impact factor: 7.727

4.  Alterations of the Notch pathway in lung cancer.

Authors:  Britta Westhoff; Ivan N Colaluca; Giovanni D'Ario; Maddalena Donzelli; Daniela Tosoni; Sara Volorio; Giuseppe Pelosi; Lorenzo Spaggiari; Giovanni Mazzarol; Giuseppe Viale; Salvatore Pece; Pier Paolo Di Fiore
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-10       Impact factor: 11.205

5.  Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context.

Authors:  Carmen Guerra; Nieves Mijimolle; Alma Dhawahir; Pierre Dubus; Marta Barradas; Manuel Serrano; Victoria Campuzano; Mariano Barbacid
Journal:  Cancer Cell       Date:  2003-08       Impact factor: 31.743

6.  Stage-specific sensitivity to p53 restoration during lung cancer progression.

Authors:  David M Feldser; Kamena K Kostova; Monte M Winslow; Sarah E Taylor; Chris Cashman; Charles A Whittaker; Francisco J Sanchez-Rivera; Rebecca Resnick; Roderick Bronson; Michael T Hemann; Tyler Jacks
Journal:  Nature       Date:  2010-11-25       Impact factor: 49.962

Review 7.  Oncogenic and tumor suppressor functions of Notch in cancer: it's NOTCH what you think.

Authors:  Camille Lobry; Philmo Oh; Iannis Aifantis
Journal:  J Exp Med       Date:  2011-09-26       Impact factor: 14.307

8.  Selective activation of p53-mediated tumour suppression in high-grade tumours.

Authors:  Melissa R Junttila; Anthony N Karnezis; Daniel Garcia; Francesc Madriles; Roderik M Kortlever; Fanya Rostker; Lamorna Brown Swigart; David M Pham; Youngho Seo; Gerard I Evan; Carla P Martins
Journal:  Nature       Date:  2010-11-25       Impact factor: 49.962

9.  Therapeutic effect of γ-secretase inhibition in KrasG12V-driven non-small cell lung carcinoma by derepression of DUSP1 and inhibition of ERK.

Authors:  Pablo J Fernández-Marcos; Daniel Herranz; Antonio Maraver; Maribel Muñoz-Martin; Gonzalo Gomez-Lopez; Marta Cañamero; Francisca Mulero; Diego Megías; Marta Sanchez-Carbayo; Jie Shen; Montserrat Sanchez-Cespedes; Teresa Palomero; Adolfo Ferrando; Manuel Serrano
Journal:  Cancer Cell       Date:  2012-08-14       Impact factor: 31.743

10.  Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.

Authors:  Jeffrey A Engelman; Liang Chen; Xiaohong Tan; Katherine Crosby; Alexander R Guimaraes; Rabi Upadhyay; Michel Maira; Kate McNamara; Samanthi A Perera; Youngchul Song; Lucian R Chirieac; Ramneet Kaur; Angela Lightbown; Jessica Simendinger; Timothy Li; Robert F Padera; Carlos García-Echeverría; Ralph Weissleder; Umar Mahmood; Lewis C Cantley; Kwok-Kin Wong
Journal:  Nat Med       Date:  2008-11-30       Impact factor: 53.440
  10 in total
  3 in total

1.  NOTCH pathway inactivation promotes bladder cancer progression.

Authors:  Antonio Maraver; Pablo J Fernandez-Marcos; Timothy P Cash; Marinela Mendez-Pertuz; Marta Dueñas; Paolo Maietta; Paola Martinelli; Maribel Muñoz-Martin; Mónica Martínez-Fernández; Marta Cañamero; Giovanna Roncador; Jorge L Martinez-Torrecuadrada; Dimitrios Grivas; Jose Luis de la Pompa; Alfonso Valencia; Jesús M Paramio; Francisco X Real; Manuel Serrano
Journal:  J Clin Invest       Date:  2015-01-09       Impact factor: 14.808

2.  Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma.

Authors:  Emilie Bousquet Mur; Sara Bernardo; Laura Papon; Maicol Mancini; Eric Fabbrizio; Marion Goussard; Irene Ferrer; Anais Giry; Xavier Quantin; Jean-Louis Pujol; Olivier Calvayrac; Herwig P Moll; Yaël Glasson; Nelly Pirot; Andrei Turtoi; Marta Cañamero; Kwok-Kin Wong; Yosef Yarden; Emilio Casanova; Jean-Charles Soria; Jacques Colinge; Christian W Siebel; Julien Mazieres; Gilles Favre; Luis Paz-Ares; Antonio Maraver
Journal:  J Clin Invest       Date:  2020-02-03       Impact factor: 14.808

3.  Sp1-mediated microRNA-182 expression regulates lung cancer progression.

Authors:  Wen-Bin Yang; Ping-Hsin Chen; Tsung Hsu; Tzu-Fun Fu; Wu-Chou Su; Hungjiun Liaw; Wen-Chang Chang; Jan-Jong Hung
Journal:  Oncotarget       Date:  2014-02-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.